Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab Meeting Abstract


Authors: Passaro, A.; Yu, H. A.; Nguyen, D.; Lee, V. H. F.; Soo, R. A.; Kim, S. H.; Daga, H.; Tan, D. S. W.; Kim, S. W.; Juan Vidal, O. J.; Piotrowska, Z.; Keeton, E. K.; Liu, T.; Li, S.; Jones, J.; Ruiter, G.
Abstract Title: Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
Meeting Title: ESMO Congress 2024
Journal Title: Annals of Oncology
Volume: 35
Issue: Suppl. 2
Meeting Dates: 2024 Sep 13-17
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2024-09-01
Start Page: S803
End Page: S804
Language: English
ACCESSION: WOS:001326612901557
DOI: 10.1016/j.annonc.2024.08.1311
PROVIDER: wos
Notes: Meeting Abstract: 1254MO -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Helena Alexandra Yu
    283 Yu